Pomerantz Law Firm Warns Hims & Hers Health, Inc. Investors of Class Action Deadline
On July 27, 2025, Pomerantz LLP announced that a significant class action lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS). This legal action serves as an important reminder for investors who may have experienced financial losses related to this company. Investors connected to Hims & Hers are urged to contact Danielle Peyton at Pomerantz for guidance regarding their potential claims. Those affected are encouraged to provide personal details, including their mailing address and the number of shares they acquired.
The class action centers on allegations that Hims & Hers, along with specific officers and directors, may have engaged in securities fraud and adopted unlawful business practices. As a member of the class, investors have the opportunity to seek designation as the Lead Plaintiff. The deadline for this is August 25, 2025. Interested parties can obtain additional information and a copy of the formal Complaint at the Pomerantz website.
This lawsuit comes after two notable events in the history of Hims & Hers. On April 29, 2025, the company announced a promising long-term partnership with prominent pharmaceutical company Novo Nordisk, launching with the distribution of Wegovy®, an FDA-approved medication, through the Hims & Hers platform. However, this collaboration was cut short. On June 23, 2025, Novo Nordisk revealed its decision to terminate the partnership, highlighting issues concerning Hims & Hers' marketing tactics and the sale of questionable, unauthorized versions of Wegovy®.
Novo Nordisk's press release was alarming, indicating that Hims & Hers had been accused of endangering patient safety due to its misleading promotional strategies. Specifically, the investigation revealed that Hims & Hers had not complied with legal standards that prohibit the mass sale of compounded medications under false pretenses of 'personalization.' The company had allegedly been distributing versions of the drug that were manufactured under unregulated and unsafe conditions, raising serious concerns about the quality and safety of the drugs sold.
Reacting to the termination of their partnership, Hims & Hers faced a significant decline in its stock price, dropping by $22.24 per share or roughly 34.63%, to close at $41.98 on the same day. This sudden market reaction reflects investor fears about the implications of the allegations on the company's operations and its future. Such a drastic decline in stock value hints at a potential loss of investor confidence, which has become a critical concern for stakeholders.
Pomerantz LLP is widely recognized in the sector of corporate and securities class litigation, with a legacy of representing victims of securities fraud and corporate misconduct. Established by the late Abraham L. Pomerantz, who is often regarded as the dean of the class action bar, this firm continues to play a significant role in holding corporations accountable. Throughout its more than 85-year history, Pomerantz has achieved numerous multimillion-dollar settlements on behalf of its clients, underscoring its commitment to protecting investors’ rights.
For investors seeking damages, the deadline for participating in the proposed class action against Hims & Hers arrives soon, making it crucial for affected parties to gather information and contact the firm before the cutoff date. The developments surrounding Hims & Hers raise important questions about business ethics in securities trading and the responsibility of firms to uphold public trust. Investors must remain vigilant about the implications of corporate behavior on their investment outcomes and take proactive steps as required.
The class action centers on allegations that Hims & Hers, along with specific officers and directors, may have engaged in securities fraud and adopted unlawful business practices. As a member of the class, investors have the opportunity to seek designation as the Lead Plaintiff. The deadline for this is August 25, 2025. Interested parties can obtain additional information and a copy of the formal Complaint at the Pomerantz website.
This lawsuit comes after two notable events in the history of Hims & Hers. On April 29, 2025, the company announced a promising long-term partnership with prominent pharmaceutical company Novo Nordisk, launching with the distribution of Wegovy®, an FDA-approved medication, through the Hims & Hers platform. However, this collaboration was cut short. On June 23, 2025, Novo Nordisk revealed its decision to terminate the partnership, highlighting issues concerning Hims & Hers' marketing tactics and the sale of questionable, unauthorized versions of Wegovy®.
Novo Nordisk's press release was alarming, indicating that Hims & Hers had been accused of endangering patient safety due to its misleading promotional strategies. Specifically, the investigation revealed that Hims & Hers had not complied with legal standards that prohibit the mass sale of compounded medications under false pretenses of 'personalization.' The company had allegedly been distributing versions of the drug that were manufactured under unregulated and unsafe conditions, raising serious concerns about the quality and safety of the drugs sold.
Reacting to the termination of their partnership, Hims & Hers faced a significant decline in its stock price, dropping by $22.24 per share or roughly 34.63%, to close at $41.98 on the same day. This sudden market reaction reflects investor fears about the implications of the allegations on the company's operations and its future. Such a drastic decline in stock value hints at a potential loss of investor confidence, which has become a critical concern for stakeholders.
Pomerantz LLP is widely recognized in the sector of corporate and securities class litigation, with a legacy of representing victims of securities fraud and corporate misconduct. Established by the late Abraham L. Pomerantz, who is often regarded as the dean of the class action bar, this firm continues to play a significant role in holding corporations accountable. Throughout its more than 85-year history, Pomerantz has achieved numerous multimillion-dollar settlements on behalf of its clients, underscoring its commitment to protecting investors’ rights.
For investors seeking damages, the deadline for participating in the proposed class action against Hims & Hers arrives soon, making it crucial for affected parties to gather information and contact the firm before the cutoff date. The developments surrounding Hims & Hers raise important questions about business ethics in securities trading and the responsibility of firms to uphold public trust. Investors must remain vigilant about the implications of corporate behavior on their investment outcomes and take proactive steps as required.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.